Phase I Dose Escalation Study of 3-Weekly Intravenous DPPG2-TSL-DOX Combined with Regional Hyperthermia in Locally Advanced or Metastatic Soft Tissue Sarcoma
Latest Information Update: 26 Feb 2025
Price :
$35 *
At a glance
- Drugs Doxorubicin liposomal (Primary) ; Dexrazoxane
- Indications Soft tissue sarcoma
- Focus Adverse reactions; First in man
- Sponsors Thermosome
- 21 Feb 2025 Planned End Date changed from 1 Dec 2024 to 31 May 2025.
- 21 Feb 2025 Planned primary completion date changed from 1 Dec 2024 to 31 May 2025.
- 21 Feb 2025 Status changed from recruiting to active, no longer recruiting.